New class of antigen-specific cancer immunotherapy
based on an off-the-shelf antigen presenting cell line

News

PDC*line Pharma team wishes you and your loved ones a festive & very happy holiday season and a successful 2022!

2021-12

Read more about PDC*line Pharma team wishes you and your loved ones a festive & very happy holiday season and a successful 2022!

PDC*line Pharma raises €17.5 million ($20,3M) in Series B2 financing round

2021-12

**PDC*line Pharma raises €17.5 million ($20,3M) in Series B2 financing round**

New funding includes €11.8M in equity and €5.7M in grants. It completes the €20M B1 round of financing announced in January 2020.

Proceeds will primarily be used to fund

Read more about PDC*line Pharma raises €17.5 million ($20,3M) in Series B2 financing round

PDC*line Pharma opens last cohort of PDC-LUNG-101 clinical trial

2021-11

B2 cohort (high dose added to anti-PD-1) of the PDC-LUNG-101 trial with PDC*lung01 therapeutic cancer vaccine candidate for non-small cell lung cancer has been opened and first patients were dosed

Liège, Belgium and Grenoble, France, November 4,

Read more about PDC*line Pharma opens last cohort of PDC-LUNG-101 clinical trial

PDC*line Pharma opens last cohort of PDC-LUNG-101 clinical trial

2021-11

Liège, Belgium and Grenoble, France, November 4,

Read more about PDC*line Pharma opens last cohort of PDC-LUNG-101 clinical trial

Our CEO participated Friday October 8th as a speaker at the EU-Korea Global Vaccine partnership roundtable with Mr Han-koo Yeo, Minister for Trade of South Korea, Mr Thierry Breton EU Commissioner

2021-10

It has been a pleasure and an honor for our CEO Eric Halioua to participate Friday October 8th as a speaker at the EU-Korea Global Vaccine partnership roundtable with Mr Han-koo Yeo, Minister for Trade of South Korea, Mr Thierry Breton EU

Read more about Our CEO participated Friday October 8th as a speaker at the EU-Korea Global Vaccine partnership roundtable with Mr Han-koo Yeo, Minister for Trade of South Korea, Mr Thierry Breton EU Commissioner

linkedin twitter

PDC*line Pharma

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in clinical development (PDC*lung) and on neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France).

About us

A first in class Plasmacytoid Dendritic cell line, PDC*line providing unmatched advantages

Potent & effective

Induction of a strong cytotoxic immune response directed against a selection of tumour antigens

Scalable & convenient

Simple production of a large quantity of a highly qualified off-the-shelf product

Versatile & applicable to any cancers

The peptides can easily be changed to target a specific cancer type

Management Team

Eric Halioua

Laurent Levy

Dr. Joel Plumas

Claude DEDRY

Dr. Channa Debruyne

Candidate products

Melanoma

Melanoma is the most lethal form of skin cancer, representing 2% of all newly diagnosed cancer cases (232,000 new cases and 55,000 deaths worldwide in 2012). It is also the leading cancer in terms of incidence increase (+ 10% per year) and one of the most common cancers in young adults (18-35 years).

Melanoma is often easier to detect in its early stages than most cancers. However, it is also more likely to spread (metastasize) to other parts of the body, and 16% of patients are first diagnosed at an advanced stage. Despite new treatments, prognosis for this late-stage disease is very unfavorable (5-year mortality rate of 85%).

Read more about PDC mel

Lung Cancer

Lung cancer is the most common malignancy worldwide for male patients and for both sexes combined (2.1 million new cases per year), and the third most common for female patients (after breast and colorectal cancers). Deaths from lung cancer exceed those from any other malignancy globally, with the number of lung-cancer-related deaths worldwide for 2018 estimated at 1.8 million (Globocan 2018), representing 18.4% for both sexes. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing 80% of cases.

Read more about Lung Cancer

Technology

PDC*line, our proprietary allogeneic cell line of Plasmacytoid Dendritic Cells solves the industrial limitations faced by immunotherapies based on dendritic cells currently on the market or in clinical development. Additionally PDC*line is much more potent than conventional dendritic cells to expand anti-tumor CD8+ T cells in vitro.

About our technology